Covered recipient · General Payments record
JUN ZHANG
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$75,896.14
59 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,234.00 | 17 |
| Honoraria | $5,600.00 | 2 |
| Consulting Fee | $4,700.00 | 2 |
| Travel and Lodging | $2,989.03 | 13 |
| Food and Beverage | $2,333.49 | 23 |
| Education | $39.62 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $39,426.62 | 28 |
| AstraZeneca Pharmaceuticals LP | $12,878.55 | 8 |
| GENZYME CORPORATION | $11,544.28 | 6 |
| Novocure Inc. | $8,189.51 | 12 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,500.00 | 1 |
| Galvanize Therapeutics, Inc | $188.30 | 1 |
| BeiGene USA, Inc. | $129.26 | 1 |
| Merck Sharp & Dohme LLC | $39.62 | 2 |
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JUN ZHANG
NPI 1902175615 · CMS profile ID 1361167
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
IOWA CITY, IA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1902175615?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JUN ZHANG, NPI 1902175615, CMS profile ID 1361167. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902175615?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). JUN ZHANG, NPI 1902175615, CMS profile ID 1361167. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902175615?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- JUN ZHANG, NPI 1902175615, CMS profile ID 1361167, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1902175615?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
59 matching records · $75,896.14 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–59 of 59.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $22.00 | 02/18/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999567989 | CMS |
| Regeneron Healthcare Solutions, Inc. | $184.84 | 02/18/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999567997 | CMS |
| Regeneron Healthcare Solutions, Inc. | $135.00 | 02/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999568005 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,932.00 | 02/09/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999567981 | CMS |
| AstraZeneca Pharmaceuticals LP | $132.53 | 02/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011278957 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,498.00 | 02/07/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999567965 | CMS |
| Regeneron Healthcare Solutions, Inc. | $1,873.00 | 02/07/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999567973 | CMS |
| Regeneron Healthcare Solutions, Inc. | $121.51 | 02/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999567957 | CMS |
| Novocure Inc. | $1,200.00 | 02/02/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021070421 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $814,320.58 | 71 |
| PY2024 | Recipient | $3,423.96 | 1 |
| PY2024 | Principal investigator | $2,234,252.99 | 201 |
| PY2023 | Principal investigator | $2,744,437.72 | 180 |
| PY2022 | Principal investigator | $795,242.05 | 55 |
| PY2021 | Recipient | $11,250.00 | 1 |
| PY2021 | Principal investigator | $958,787.12 | 7 |
| PY2020 | Principal investigator | $11,915.34 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
71 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $639.58 | 12/11/2025 | Non-covered Recipient Entity University Of Kansas Health System Clinical Research Center | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220698025 |
| Principal investigator 1 | Genentech, Inc. | $16,758.00 | 11/10/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | Ipat and taxane in NSCLC | No dispute reported | 06/30/2026 | 1211678065 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $103,071.84 | 11/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF KANSAS HEALTH SYSTEM | Using microbiome to predict durvalumab toxicity in post-CCRT NSCLC patients | No dispute reported | 06/30/2026 | 1185537643 |
| Principal investigator 1 | Eli Lilly and Company | $12,896.00 | 10/20/2025 | Non-covered Recipient Entity UNIV OF KANSAS MED CNTR RSRCH INSTITUTE | A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 | No dispute reported | 06/30/2026 | 1187891826 |
| Principal investigator 1 | Eli Lilly and Company | $15,031.00 | 10/14/2025 | Non-covered Recipient Entity UNIV OF KANSAS MED CNTR RSRCH INSTITUTE | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187893218 |
| Principal investigator 1 | ABBVIE INC. | $267.00 | 09/30/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202512788 |
| Principal investigator 1 | ABBVIE INC. | $400.00 | 09/23/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202511864 |
| Principal investigator 1 | ABBVIE INC. | $15,511.23 | 09/04/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202508646 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,931.00 | 09/04/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379971 |
| Principal investigator 1 | Janssen Research & Development, LLC | $568.00 | 08/29/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379941 |
| Principal investigator 1 | ABBVIE INC. | $267.00 | 08/27/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202506027 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,122.00 | 08/22/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379824 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,436.00 | 08/20/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,950.00 | 07/28/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379978 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,772.00 | 07/28/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175380082 |
| Principal investigator 1 | ABBVIE INC. | $534.00 | 07/24/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202499670 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,862.00 | 07/24/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379923 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,525.00 | 07/17/2025 | Non-covered Recipient Entity University Of Kansas Medical Center Department Of Neurology | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220811804 |
| Principal investigator 1 | Genentech, Inc. | $29,326.50 | 07/17/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | Ipat and taxane in NSCLC | No dispute reported | 06/30/2026 | 1211678057 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $4,179.66 | 07/11/2025 | Non-covered Recipient Entity Kumc Research Institute, Incorporated | A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation | No dispute reported | 06/30/2026 | 1236531028 |
| Principal investigator 1 | ABBVIE INC. | $3,962.21 | 07/09/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202497688 |
| Principal investigator 1 | ABBVIE INC. | $1,455.56 | 07/02/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202496521 |
| Principal investigator 1 | ABBVIE INC. | $15,014.35 | 07/02/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202496619 |
| Principal investigator 1 | ABBVIE INC. | $267.00 | 07/01/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202493843 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $13.30 | 06/24/2025 | Non-covered Recipient Entity University Of Kansas Health System Clinical Research Center | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996622 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $7.10 | 06/24/2025 | Non-covered Recipient Entity University Of Kansas Health System Clinical Research Center | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996624 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1.55 | 06/24/2025 | Non-covered Recipient Entity University Of Kansas Health System Clinical Research Center | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996626 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,659.00 | 06/23/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379908 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,763.00 | 06/20/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379766 |
| Principal investigator 1 | ABBVIE INC. | $426.94 | 06/18/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202492079 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $33,266.50 | 06/12/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC | No dispute reported | 06/30/2026 | 1184206713 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 06/12/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A PHASE 2 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CEMIPLIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RESECTABLE EARLY STAGE (STAGE II TO IIIB [N2]) NSCLC | No dispute reported | 06/30/2026 | 1184206715 |
| Principal investigator 1 | ABBVIE INC. | $94.79 | 06/11/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202490831 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $101,050.80 | 06/11/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER CYSTIC FIBROSIS PROGRAM | Using microbiome to predict durvalumab toxicity in post-CCRT NSCLC patients | No dispute reported | 06/30/2026 | 1185537645 |
| Principal investigator 1 | ABBVIE INC. | $267.00 | 06/05/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202490337 |
| Principal investigator 1 | ABBVIE INC. | $7,865.42 | 06/03/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202487395 |
| Principal investigator 1 | Janssen Research & Development, LLC | $241.00 | 05/30/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379949 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,579.00 | 05/29/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379987 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $81.62 | 05/27/2025 | Non-covered Recipient Entity University Of Kansas Health System Clinical Research Center | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996614 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $59.94 | 05/27/2025 | Non-covered Recipient Entity University Of Kansas Health System Clinical Research Center | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996616 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $146.00 | 05/27/2025 | Non-covered Recipient Entity University Of Kansas Health System Clinical Research Center | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996618 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2.76 | 05/27/2025 | Non-covered Recipient Entity University Of Kansas Health System Clinical Research Center | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996620 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,129.00 | 05/22/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379816 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $48,686.04 | 05/18/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER ANESTHESIOLOGY | Using microbiome to predict durvalumab toxicity in post-CCRT NSCLC patients | No dispute reported | 06/30/2026 | 1185537641 |
| Principal investigator 1 | Janssen Research & Development, LLC | $346.00 | 05/12/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379783 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,687.00 | 05/12/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175380037 |
| Principal investigator 1 | Janssen Research & Development, LLC | $773.00 | 05/12/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175380067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,737.00 | 05/12/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175380147 |
| Principal investigator 1 | ABBVIE INC. | $736.93 | 05/08/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202484385 |
| Principal investigator 1 | ABBVIE INC. | $8,960.75 | 05/07/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202483065 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,290.00 | 04/28/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175380028 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,413.00 | 04/25/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175380125 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,640.00 | 04/25/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175380140 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,508.00 | 04/24/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175380021 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $34,957.63 | 04/16/2025 | Non-covered Recipient Entity Kumc Research Institute, Incorporated | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236531020 |
| Principal investigator 1 | BeiGene, Ltd. | $96.12 | 04/11/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1190320738 |
| Principal investigator 1 | ABBVIE INC. | $14,943.82 | 04/08/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202474998 |
| Principal investigator 1 | ABBVIE INC. | $4,030.83 | 04/03/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202472479 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,184.00 | 03/24/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175380091 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,625.00 | 03/20/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379775 |
| Principal investigator 1 | Genentech, Inc. | $1,425.00 | 03/14/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | Tira atzo with or without chemo in neoadjuvant NSCLC | No dispute reported | 06/30/2026 | 1211677934 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 03/10/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379724 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,640.00 | 03/10/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379996 |
| Principal investigator 1 | ABBVIE INC. | $18,576.91 | 03/07/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | M23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202461083 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $22,385.38 | 03/03/2025 | Non-covered Recipient Entity Kumc Research Institute, Incorporated | A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio | No dispute reported | 06/30/2026 | 1236531024 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $139,003.82 | 03/03/2025 | Non-covered Recipient Entity Kumc Research Institute, Incorporated | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236531035 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,391.00 | 02/20/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379882 |
| Principal investigator 1 | ABBVIE INC. | $400.00 | 02/18/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | M23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202452272 |
| Principal investigator 1 | ABBVIE INC. | $5,738.79 | 02/06/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | M23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202448167 |
| Principal investigator 1 | Eli Lilly and Company | $284.91 | 02/03/2025 | Non-covered Recipient Entity STATE OF KANSAS/UNIVERSITY OF KANSAS MEDICAL CENTER | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187889704 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,958.00 | 01/20/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175379955 |